OPRX, US68401U2042

OptimizeRx stock expands access to 800,000 providers remains below its yearly high lacks? no

Published on 10/05/2026 at 19:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

OptimizeRx stock was trading at USD 8.64 on October 5, 2026, as its OpenPath network reached 800,000 verified HCPs. Q2 revenue fell to USD 20.504 million.

OPRX, US68401U2042, Illustration mit AI erstellt.

OptimizeRx Corp. (ISIN US68401U2042) was trading at USD 8.64 on Nasdaq on October 5, 2026, giving the company a market capitalization of USD 162.0 million. The latest operating story is the September 22 OpenPath integration, which expands access to more than 400 electronic health record and e-prescribing systems reaching 800,000 verified healthcare professionals, according to MarketScreener on September 22, 2026.

OpenPath broadens healthcare reach

The integration connects OptimizeRx point-of-care inventory with The Trade Desk's programmatic buying platform. The company said the inventory is expected to become available through OpenPath in the fourth quarter of 2026, creating an additional distribution route for its EHR network.

The commercial opportunity is tangible but still forward-looking. Advertisers gain direct access to verified provider inventory inside broader media strategies, while OptimizeRx gains another route to life sciences demand beyond specialized healthcare buying.

Q2 revenue fell 29.8 percent

The latest quarter showed the execution challenge clearly. Revenue declined from USD 29.195 million in Q2 2025 to USD 20.504 million in Q2 2026, while net income shifted from a USD 1.532 million profit to a USD 0.703 million loss, according to Simply Wall St on October 4, 2026.

Gross margin nevertheless reached 76.5 percent in Q2 2026, while fiscal-year 2026 guidance remained at USD 95 million to USD 100 million of revenue and USD 21 million to USD 25 million of adjusted EBITDA, as Seeking Alpha reported on September 18, 2026.

Analyst target stays above Nasdaq price

MarketBeat reported a Moderate Buy consensus from nine analysts on September 20, 2026, with six Buy ratings, two Holds and one Sell. The average 12-month price target was USD 11.43 versus a reported USD 7.29 share price, according to MarketBeat. B. Riley also raised its target from USD 10 to USD 11 on September 29, 2026, while maintaining a Buy rating, MarketBeat reported.

OPRX remains below its yearly high

At USD 8.64 on Nasdaq at 1:22 p.m. ET on October 5, 2026, OPRX stood 61.17 percent below its 52-week high of USD 22.25 and above its 52-week low of USD 4.54. The combination of a 76.5 percent quarterly gross margin and a 29.8 percent year-over-year revenue decline leaves OpenPath adoption and the 2026 guidance range as the key operating checkpoints.